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ABSTRACT
Extrac0 'l)o rea l ph oroch cmotherapy (EP) is a th erapeutic approach to th e t reatment of drug-resistant graft-vs .- host
disease (GV1ID) th at uses the known im m unosuppressive and imm uno mod ulatory effects of ul traviolet ligh t. In
1990 , we initiat ed a pilot study to evalua te the efficacy and safety of EP in patients with refractory GVI-I D. Bet ween
1991 and 1996, six pati ents with acute grade IV liver G VIID, 12 pari cnts with ch ro nic following acute GVIID, and
six patien ts with til' 1I0VO ch ro nic GVI-ID were treat ed with EP. All parienrs had failed to respond to co nve ntio na l
GVI ID im m unos upp ressive drug th e rap y of cyc los poriue and prednisone. T he six pati en ts with acure liver GVH D
had also received an rirhymocyte glohulin (ATG); th e rapy for chronic GVH D inc lude d th al idom idc in cig ht patients,
I)so ralcn plu s ulrraviol et A in five parients, and ATG in two pari cnrs. All parients with ac ute liver GVIID had pro-
grcssivc liver failure with short survival despite fre q ue nt EP. The response ra te with EP trenrm ent was 3 of 6 for
patients with tic 110 110 chronic GVH D and 3 o f 12 for pat ients with chronic following acute GVI-I D. T hree pati ents
with bronchiolitis obl ire run s had ei the r no resp on se o r no documented disease p rogression whil e undergoing EP.
Sidc effects of E P wc rc minor and included gasrr o inrcs ti na l up set fre q uc ntly, ca rhe rer- re lnrcd se psis in four
pati ents, inc re ased re d blood ce ll and pluteler tran sfu sion requirem enrs in one pati ent, and leukopenia in two
pati ents. EP was discontinued in three puricnrs becau se of side effec ts, including G I up set in on c pa rieur and hon c
marr ow suppression in tw o patients. Side effects were reversible with th c discontinuat ion o f E P. \ \'e we re un abl e to
correlate res po nse to EP with th c level of methoxypso rnlen , number of Iymphocyres t reat ed , or pattern of prc- and
po srt reutmcnt C D4/C D 8 ratio. \Vc co nc lude d th at EP has so me CIliC'ICY in th e treatment o f drug-resistant chronic
GVI ID, with minor overall to xicit y.
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INTRODUCTION
111 .~~ r.~ ft- vs .- h os t di sea se «(; V 1-1 D ) is a frequ ent cause of
( B~~/~ I I\ Y an d mo rt al ity aft er hone marrow tran splantation
I ) from re lat ed and unrelated hisrocomparih lc donors
'/1 '
e:;' ~"I'~' uas JllppOI'I,·" ill PIII'I I~y U.S. /'1I b1i( ll ealtb Srruic» gl"lllllJ
" llJ.lJfi 1111" e ·1;; ,)7! [nn» tbr Nation«!Cane..1' lnstitutr.
and is the sing lc most important ob stacle to success ful allo -
genc ic BJVn : Development of eVil D after IIMT is mediated
hy nlloreu ctivc do no r T lym phocyt e subse ts, which become
activated aft er reco gnirion of major histo compatihili ry com -
plex (,\ 'lI fe) antigen s or minor histocompatibi lity antigen s of
th e host, or both , that arc di sparat e from donor anti gcn s.
Recen t experimcnru l data suggcs t that direc t ce ll- me d iated
arrack of donor T lymphocy tes Oil ho st tissues is onl y on e of
several mechanism s lendin g 1lI host tissue dam ugc 11 ,2/ , As
ATG, antithymoeyte globulin; CML, chronic myeloid leukemia; CSA, eyclo-
sporine; CY, cyclophosphamide; PTBI, fractionated total-body irradiation;
GVllD, graft-vs.-host disease; llLA, human leukocyte antigen; MDS,
myelodysplastic syndrome; MTX, methotrexate; PSE, prednisone; TU, total-
lymphoid irradiation.
discussed in several recent reviews, several lines of evidence
now implicate a network of cytokines as primary mediators of
experimental and clinical GVHD [3-61. T cell depletion of
the marrow graft to limit the cascade of cytokine production
that results from the complex interactions of subsets of T
cells, antigen presenting cells, and accessory effector cells
decreases the incidence of GVHD, but also significantly
increases the risk of graft failure and leukemic relapse [7].
Acute GVHD in the first 100 days post-BMT is a patho-
logic process characterized by cytolytic damage to the host
target tissues of skin, liver, and gastrointestinal tract, with
accompanying systemic symptoms of fever and increased cap-
illary permeability. Prophylaxis of acute GVHD with combi-
nations of immunosuppressive agents has decreased the inci-
dence of this complication of BMT to 20-25% in recipients
of unmodified (i.e., no ex vivo T cell depletion) allografts
from human leukocyte antigen (HLA)-identical siblings, but
it remains a primary or contributory cause of death in
15-20% of marrow transplant patients [8]. Treatment of
established acute GVHD with steroids, cyclosporine (CSA),
monoclonal antibodies, and antithymocyte globulin (ATG)
has been characterized by high failure rates, significant drug
toxicities, and poor survival for nonresponders [9-13].
Chronic GVHD (cGVHD) is the primary cause of non-
relapse morbidity and mortality in patients surviving longer
I
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Table I. Patient characteristics
Number of patients
Median age (range)
Male/female
Diagnosis
CML
Acute leukemia
Aplasticanemia
MDS & myeloproliferative diseases
Donor status
HLA·ldentical sibling
5/6 HLA sibling
Matched unrelated donor
Transplant preparative regimens
FlBI and etoposide
FlBIand CY
FlBI, CY, and etoposide
CY and busulfan
TUand CY
cy
GVHD prophylaxis
CSA and PSE
CSA, PSE, and MTX (days 1,3,6)
CSA, PSE, and MTX (days I. 3, 6, II)
CSA
CSA, PSE, and ATG
Acutegrade IV liver GVHD
De novo chronic GVHD
ChronicGVHD after acute GVHD
24
29 years (5.7-53)
19/5
II
8
2
3
17
I
6
II
5
3
3
I
I
7
12
3
I
I
6
6
12
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than 100 days after BMT: The clinical syndrome resembles
an overlap of various autoimmune diseases, such as progres-
sive systemic sclerosis, Sjogren's syndrome, systemi~ lup~s
erythematosus, lichen planus, and primary biliary CIrrhOSIS
[14,15]. Because the pathophysiology of this disease pro~~ss
includes the production of autoantibodies and the inablh~
to produce protective antibodies against environment~
pathogens, it has been suggested that the primary defect m
cGVHD is an imbalance between autoreactive and autore~­
ulatory T cells [16]. cGVHD occurs in 20-50% of r~ci'pl­
ents of unmodified (i.e., no ex vivo T cell depletion) slbhng
marrow transplants, with mortality rates varying from 20.t~
70%, depending on the presence of known associated ns
factors for poor outcome [17]. .
Because prevention and treatment of acute and chron~c
GVHD has been less than ideal, alternative ther~pe~t1~
approaches are desirable. One novel approac~ IS .p ~e
tochemotherapy, also known as PUVA therapy, whIch IS
use of oral methoxypsoralen (8-MOP) photoactivated 7
exposure of skin to ultraviolet A (UVA) light. Multiple stu •
ies have demonstrated the efficacy and safety of pUVA ther-
apy in the treatment of cutaneous GVHD [18-25]. Extra-
corporeal photochemotherapy (EP), also referred to as pho-
topheresis, is a variant of PUVA therapy that involves extrad
corporeal exposure of blood lymphocytes to UVA followep
by reinfusion of the treated cells. Bolwell etal. first used E
in the treatment of GVHD; in 1990 they reported the suc-
cessful treatment of cGVHD in two of three patients [261:
1To extend the experience with EP, we conducted a pi ot
study with 20 patients from 1990 to 1994 in which we evalu-
ated the efficacy and safety of photopheresis in the treatrneft
of drug-resistant acute and chronic GVHD. Since the pub ~­
cation of our original abstract [27], we have treated an addi-
tional four patients who are included in this report, and h~~
summarize our results from EP treatment of 24 patients WI
acute and chronic drug-refractory GVHD.
MATERIALS AND METHODS
Patient population
Between February 1991 and February 1996, 24 patients
with drug-resistant acute and chronic GVHD were treated
with EP at the City of Hope National Medical Center
(COH). The initial 20 patients were treated in a non-ran-
domized pilot study conducted from 1990 to 1994 to evaluf
ate the efficacy and safety of EP in the management?
refractory GVHD. Subsequent to the pilot study closure In
1994, we treated an additional four patients, whose data are
included in this report. .
Patient characteristics are shown in Table 1. The medI-
an age of marrow recipients was 29 years, with a range of
5.7-53 years. There were 19 male and 5 female patients.
The indications for BMT were chronic myelogenoUS
leukemia (n = 11); acute leukemia, including acute lym-
phoblastic leukemia, acute myelogenous leukemia, and aeut~
biphenotypic leukemia (n=8); aplastic anemia (n=2); an
myeloproliferative and myelodysplastic disorders (n=3).
Donor-recipient matching
The histocompatible marrow donors were 6/6 liLA-
identical siblings (n= 17), 5/6 lILA-matched siblings (n> 1),
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started, all patients with acute GVHD received 2 mglkg of
PSE for longer than 2 weeks and were continued on that
same dose after initiation of EP. Twelve patients with chron-
ic following acute GVHD and six patients with de novo
cGVlID who failed to respond to standard therapy, which
included thalidomide (eight patients) and PUVA (five
patients), were treated with EP. Initial standard therapy for
cGVHD patients included at least 10 days of therapy with 2
mglkg/day of PSE plus CSA in doses to achieve therapeutic
levels. The cGVHD patients were eligible for EP treatment
if their cGVHD flared as steroids were tapered so that they
were on varying doses of PSE at the time EP was started,
but all were on CSA doses that resulted in therapeutic CSA
levels. Two of the cGVlID patients with prior acute GVHD
also had received ATG for treatment of acute GVHD.
Characteristics of patients' cGVHD before therapy with EP
are outlined in Table 2.
Extracorporeal photopheresis
Treatment with EP was accomplished using the UVAR
photopheresis system (Therakos, West Chester, PA), which
is diagrammed in Figure 1. The photosensitizing agent was
8-MOp, a furocoumarin that forms covalent bonds with the
pyrimidine bases of DNA in the presence of UVA light. The
drug preparation used in this study was Oxypsoralen Ultra
(ICN Pharmaceuticals, Costa Mesa, CA). The initial oral
dose of 8-MOP was 0.6-1.0 mg/kg and the dose was adjust-
ed with subsequent treatment cycles in an effort to achieve a
therapeutic level of >50 ng/mL. The 8-MOP dose was
increased by 25% if the patient had a subtherapeutic level
with the previous cycle of EP. If the patient's 8-MOP level
increased with this dose titration but was still subtherapeu-
tic, then the dose was sequentially increased in 25% incre-
ments with subsequent cycles until a therapeutic dose was
achieved. However, if there was no change in the patient's 8-
MOP level after doubling the initial dose, then that patient
was assumed to have an inability to absorb the drug and fur-
ther dose adjustments were not made. The therapeutic level
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~r ?1~tched unrelated donors (n=6). Four unrelated donor-
ae~Plent pairs were serologic matches for class I antigens
dn molecular matches for class II antigens; one unrelated
aon°r-recipient pair had a micro-mismatch at a B locus and
d mo ecular match at class II antigens; and one unrelated
w?~Or-recipient pair was serologically matched at all loci
m
l
. a nonreactive mixed leukocyte culture (MLC). (lnfor-
b atlon regarding molecular matching was unavailable to us
ecause the patient was transplanted at another institution.)
Transplant "preparative regimen
p d!w~nty-two patients underwent BMT at COlI and two
s\Iatrlc patients underwent BMT at other institutions and
G\1;Quently were referred to COlI for treatment of
r . J? Preparative regimens varied according to disease,
tiemlsslon status, and active institutional protocols at the
[2~3of each patient's BMT and were previously reported
l320 2]. The regimens used for patients with leukemia were
m /kcGy fractionated total-body irradiation (FTBI) plus 60
rng/kg of etoposide in 11 patients; 1320 cGy FTBI plus 120
olBg of CYclophosphamide in 5 patients; a triple regimen
(20 20 cGy FTBI plus 60 mglkg of etoposide and cytoxan
III ;g/kg In one patient and 40 mg/kg in another); and 16
o g g ~f busulfan plus 120 rng/kg of cyclophosphamide in:~~atlent. One patient with aplastic anemia received 50
p~ . g~day of cytoxan for 4 days plus 750 cGy total-lym-
r ol.d Irradiation and another patient with aplastic anemia
~Ceted eytoxan alone. Patients with myeloproliferative or
bye fdysplastic disorders received a regimen of 16 mg/kg ofc~u fan plus 120 mglkg of cytoxan (n=2 patients) or 1200
et y F!BI plus 80 mg/kg of cytoxan plus 60 mg/kg of
w°poslde (n= 1 patient). Ex vivo marrow T cell depletion
asnot used.
GVHD prophylaxis
th AC~te GVHD prophylaxis regimens varied according to
nM~t1ve institutional protocols at the time of each patient's
th and have been reported elsewhere. The regimens that
n .ese patients received were cyclosporine (CSA) and pred-
~sone (PSE) in seven patients [33]; CSA, PSE, andc~~otrexate(MTX) on days 1, 3, and 6 in 12 patients [34];
p . ' PSE, and MTX on days 1, 3, 6, and 11 in three
a~~ents ~29]; and CSA alone in one patient [35]. One pedi-
c c patient, who underwent BMT at another transplant
ienter, received a regimen of CSA, PSE, and ATG accord-
r~~i t? that institution's GVHD prophylaxis protocol for
plents of unrelated donor marrow transplants.
Diagnosis of GVHD
w The diagnosis and grading of acute and chronic GVHD
stsmade by COlI clinical investigators according to the
. a~dard criteria previously described by the transplant team~n eattle [36]. Biopsies of skin and gut were performed ton~nfir~ the diagnosis of GVHD in the majority of cases.
biOpsies of liver and lung were infrequently performed
thcause, in many cases, the clinician responsible thought
p at the procedure was unsafe due to aberrant coagulation
arameters. Diagnosis of mouth cGVHD was made without
~nfirmatory biopsy. Six patients with acute grade IV liverC~7HD who had failed to respond to standard therapy with
A, PSE, and ATG were treated with EP. When EP was
Table 2. Characteristics ofchronic GVHD at studyentry
Number of patients
Chronic GVHD site
Skin
Skin and mouth plus hepatic dysfunction
Progressive liver
Progressive liver plus mouth or skin
GI plus liver (or mouth and skin)
Bronchiolitis obliterans
Prior acute GVHD
Progressive from acute GVHD
De novo GVHD
Thrombocytopenia
Prior treatment for chronic GVHD
PSE/CSA
Thalidomide
PUVA
ATG for prior acute GVHD
GI, gastrointestinal; PUVA, psoralen plusultraviolet A light.
18
2
3
4
4
2
3
12
8
6
II
18
8
5
2
lJB&MT 29
EPSmithet0/.
Orallntaka of &-MOP (0.8 -1.0 mg/kg)
1.8 - 2.0 houra ""ora conactlng cana
Collactlon of bUffy coat/plaama
fraction ovar 8 cyclaa of
dlacontlnuoua flow laukapha..ala
Figure I. Schema of extracorporeal photochemotherapy using the
UVAR photopheresls system for cell collection and Irradiation
8·MOP drug levels
Patient blood samples for 8·MOP levels were collected
in heparinized blood collection tubes 2 hours after ingestion
of 8-MOP and before the photopheresis procedure. The
plasma fraction was then separated by centrifugation and
placed in a polypropylene tube. The assay for 8-MOP levels
was performed by the high pressure liquid chromatography
method at the Yale University Photobiology Laboratory
(New Haven, en
Statistical methods
The primary objective of this study was to estimate the
response rate when EP was used to treat drug-refrac~ory
cGVHD. Univariate and multivariate logistic regreSSiOns
were performed, with outcome being treatment success or
failure, to evaluate whether any treatment variables were
predictive of treatment outcome. The covariates that were
tested to determine if they influenced the outcome of treat#
ment included the following: total number of lymphO~~
treated per procedure and per course, the number of
treatments, days between first and last treatments, and 8#
MOP dose. The 8-MOP dose was quantified in the follow#
ing ways: total dose across all treatments, average d'fsefhighest single dose, dose >50 ng/mL for more than halJ:
the treatments, dose > 100 ng/mL for more than half of e
treatments, dose >50 ng/mL for at least one treatmenddose >50, 75, and 100 ng/mL for any two treatments, an
dose >50, 75, and 100 ng/mL for any three treatme~ts.
Another point of interest was overall survival, measurl~g
time from start of EP to death or date of last contact. T e
survival curve for the patients with cGVHD was drawn
using the product-limit method of Kaplan and Meier.
EP regimen of 2-3 procedures per week. Respondin.g
patients continued to receive EP until they achieved mar
mal response and then intervals between treatment eye e~
were slowly increased. The time schedule for tapenng E.
was determined on an individual basis by the patient's. ~rl#
mary transplant physician and the transfusion mediCine
physician. All patients were on CSA and PSE, and some
patients were also on thalidomide before entry in this study
and were continued on the same doses of their immunosup#
pressive medications when EP was initiated. In patientS
. e
who responded to EP, the doses of immunosuppresslV
medications were progressively reduced as tolerated.
Flow cytometry d
Enumeration of CD4 and CD8 cells in peripheral bloo
samples was performed with flow cytometry, Patient sa~plef
were collected before the start and after the completion 0
the EP course. Samples were stained with fluorochrome#
labeled CD4 and CD8 antibodies (Becton Dickinson
Immunocytometry Systems, San Jose, CA). LYSIS 2 data
acquisition was performed and analyzed using FACScan
(Becton Dickinson Immunoeytometry Systems).
Evaluation of response
Response was defined as a 50% or better improveme?t
in measurable parameters of GVHD, i.e., extent of skin
involvement, total bilirubin and alkaline phosphatase val#
ues, volume of diarrhea, and pulmonary function tests.
Pulmonary function was assessed by spirometry with m~as#
ure of forced vital capacity, forced expiratory volume 111 1
second, maximal midexpiratory flow, maximal expirato~
flow rate, and maximal expiratory flow,at 50 and 75% 0
expired vital capacity.
The primary transplant physician for each patient and
the transfusion medicine physician (1.S.) who treated all
patients in this study performed serial assessments of the
skin's appearance in terms of the amount of induration or
softness and the presence or absence of ulcerations and ero-
Total
Therapy
Time-
3.5 hra
Irradiation 01calla during
laukapha..ala for 1.5 houra
Irradiation of tha final buffy
coat product for 1.8 hou..
Ralnfualon of UVI"adlatad calla
Into patlant for 0.5 houra
UVA
Irradiation
Treatment plan
The schedule of EP treatments varied during the course
of this study. Patients with cGVHD were initially treated
on a schedule of 2 consecutive procedures every 3 weeks for
the treatment of cutaneous T cell lymphoma, as reported
by Edelson et Ill. [37]. Subsequently, the treatment schedule
for patients with extensive cGVHD was intensified to 2-3
procedures per week, based on a hypothesis that more
intensive EP might yield greater therapeutic benefit. All
patients with acute GVHD were treated with an intensive
of 8-MOP was defined as 50 ng/mL based on extrapolation
from the photobiology literature regarding the use of EP for
the treatment of cutaneous T cell lymphoma [37]. Two
hours after ingesting 8-MOp, patients underwent a discon-
tinuous leukapheresis procedure, which resulted in the col-
lection of a buffy coat preparation that contained an estimat-
ed 25-50% of the total peripheral blood mononuclear cell
compartment. The final buffy coat product was then circu-
lated as a l-rnm film through a sterile cassette surrounded by
a UV light source, which yielded an average exposure per
lymphocyte of 2 J/cm2• After photoactivation, the UVA-
exposed leukocyte preparation was returned to the patient.
The entire procedure lasted 3.5 hours.
30
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-Table J S h
• c edule ofEP treatmentsfor patients with GVHD
Total number
lymphs Average
Interval treatedl number
Number between course of lymphs 8·MOP
No' UPN
Donor Days of EP EP 1st & last therapy treated/EP dose Level ng/mL
-
type post.8MT processes schedule EP (days) (x 109) (x 109) (mg) (median [range]) Outcome
I 565
2 MSD 538 10 2 EP q. 3 weeks 85 24.1 2.4 SO ISO (120-184) PR skin; death444 MSD 1414 19 2 EP q, 3 weeks 260 35.1 1.95 50 117 (0-262) CRskin; alive3 726 MSD 83 26 3 EP q. week 89 76.1 2.9 70 83 (0-242) NR; alive4 001 MSD 457 15 2-3 EP q. week 95 28.3 1.9 50 101 NR; death5 693 MSD 182 22 2 EP q. 2 weeks 148 42.77 1.94 70 352 (106-507) R then prog;
6 death631 MSD 602 6 2 EP q. week 19 2.03 0.4 50 288 NR; death7 525 MSD 784 48 2 EP q. month; then 539 144.27 3.0 50 104 (0-515) CR liver; alive
8 2 EP q. 3 weeks2021 URD 326 18 2 EP q. week 59 20.8 1.15 40 73 (0-116) NR; death9 732 MSD 153 16 2 EP q. week 52 12.2 0.8 70 50 (40-75) NR; alive10 465 MSD 1333 25 2-3 EP q. week 101 49.71 1.99 40 152 (102-230) CR liver, skin;
II alive595 MSD 694 46 3 EP q. week 113 47.9 1.1 50 150 (50-270) NR; death12 561 MSD 414 22 2 EP q. 3 weeks 175 57.2 2.6 40 0(0-0) NR; death13 650 MSD 282 26 2 EP q. 3 weeks 117 66.04 2.54 40 118 (0-383) PR liver; alive14 604 MSD 373 14 2 EP q, 3 weeks; then 113 15.5 1.14 50 75 (28-122) NR; death
15 2 EP q. 2 weeks537 MSD 1051 30 2 EP q. 3 weeks; then 132 126.9 4.2 70 29 (0-113) R then prog;
16 2 EP q. week death2105 URD 58 28 3 EP q. week 103 17.55 0.65 5.4 0(0-270) PR skin; alive17
18
844 MSD 821 6 2 EP q. week 30 2.5 0.42 50 35 NR; death
2125 URD 154 14 2 EP q. week 58 36.04 2.57 40 12 (0-27) NR; death19
20
002 URD 134 20 2 EP q. week 24 22.3 1.1 20 50 (0-148) NR; death
21
721 MSD 97 4 3 EP q. week II 1.7 0.4 70 87 (0-173) NR; death
22
2022 5/6 MSD 54
"
2 EP q. week 21 5.8 0.53 30 42 (36-49) NR;death
23
727 MSD 56 24 3 EP q. week 61 12.2 0.5 50 322 (283-361) NR; death
2030 URD 106 23 2 EP q. 3 weeks; then 59 49.4 2.1 50 123 (120-126) NR; death
24 3 EP q. week
----!138 URD 50 16 3 EP q, week 47 6.02 0.40 60 0(0-0) NR; death
'Plltients ICR, -18 havecGV1ID; patients 19-24 haveacute GV1ID.
complete remission of GVIID; EP, extracorporeal photochemotherapy; MSD, matched sibling donor; NR, no response; PR, partial remission of GVHD;
9·, every; R thenprog, response thenprogression ofGV1ID; UPN, unique patientnumber; URD, unrelated donor.
~o~S ..If both physicians documented resolution of the
tha)onty of the skin ulcerations and softening of the skin,
r en the patient was considered to have had a response. A
SeSponse for patients with mouth cGVHD consisted of
Ytnptomatic improvement in terms of less pain and an abili-~ ~ eat, as well as a physician assessment of improvement
In e appearance of the oral mucosa. Patients who had pro-
~r~ssion of GVHD while on EP were considered to have
a treatment failure.
RESULTS
Six patients with acute GVHD and 18 patients with
cGVHD were evaluable for response and toxicity. The
grhup of 18 patients with cGVHD included two patients~ ? were treated with EP before day 100 post-BMT.
nlque patient number (UPN) 2105 was treated with EP
I1I1&MT
for acute grade IV skin GVHD from day 58 through day
126 and was restarted on EP on day 140 for progressive
cGVHD of skin, mouth, and liver. UPN 726 had acute
grade III skin, grade II GI, and grade II liver GVHD, which
had progressed to skin and mouth cGVHD by day 83 when
he was started on EP. The six patients with acute grade IV
liver GVHD were treated with two EP procedures every
week (n> 1) or three procedures every week (n=5), as shown
in Table 3. Despite this schedule of frequent EP, the patients
with acute liver GVHD had progressive liver failure with
very short survival. The median number of EP procedures
that were performed in patients with acute grade IV liver
GVnD was 18, with a range of4-24.
Six patients with de novo cGVHD and 12 patients with
chronic following acute GVHD were treated with EP all a
schedule varying from 2 or 3 procedures everyweek to 2 pro-
cedures every 3 weeks (Table 3). In the patients with
31
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-Table 4. GVHD parameters: pre-andposttreatment in responders
UPN Pretreatment Posttreatment Outcome
Noncompliant and lost to follow,UP;
died 41 months post-8MT
Onset of skin ulcers on legs
at 5 years post-8MT, thuS
PSE resumed
CR of GVHD on PSE 10 mg every
other day at 8.3 years
post-8MT
CR of GVHD on neither PSE nor (SA
at 7 years post.8MT
CR of GVHD on neither PSE nor CsA
at 5 years post.8MT
De novo scleroderma with leg ulcerations;
mild mucositis
Acute followed by cGVHD of mouth & liver,
AP of 312 lUlL, bilirubin of 3.5 mgldL
De novo mucositis, lichenoid skin changes,
AP of 410 lUll, bilirubin of 3 mg/dL
Acute progressing Into cGVHD of liver;
AP 1720 lUlL, bilirubin 6 mgldL
650
565
444
525
465
De novo scleroderma; extensive ulceration of neck, Healing of all ulcerations started after 2nd EP
lower abdominal wall, back, and over sternum, and continued through 10th EP; 8 months
post-EP had I superficial erosion,
on 20 mglday of PSE
Healing of all ulcers Increased ROM by 7th EP,
permitting thalidomide taper; all but I ulcer
resolved after 10th EP; PSE gradually tapered
during 19 procedures
After I month of 3 EP/week, PR of skin and
mucositis, APof 112 lUlL,bilirubin of 0.9 mgldL,
PSE tapered during 25 EP procedures
After 12 months of EP, AP of 994 lUlL,
bilirubin of 2.2 mg/dL on 20 mgld of PSE;
EP stopped after 48 procedures
After 26 EP procedures, AP of 964 lUlL,bilirubin of
1.3 mg/dL on 10 mgld of PSE, 100 mgld of CSA;
sustained PR of liver cGVHD post.EP;
CSA and PSEtapered to zero
2105 Acute grade IVskin with bullous lesions of Complete healing of 95% of skin surface, Stable cGVHD of skin and mouth
entire body on day 58 while patient on permitting taper of PSEto 3 mglkgld at 13 months post.8MT on PUVA,
4 mg/kgld of PSE; no response to ATG, by day 128 2.5 mglkld of CSA, and
developed cGVHD ofskln, mouth, and Restarted EP on day 140 with stabilization 0.125 mg/kgld of PSE
liver when EP stopped on day 126 of cGVHD _
AP, alkaline phosphatase; BMT, bone marrow transplant; cGVHD, chronic graft-vs.-host disease; CR.complete remission; EP,extracorporeal photopheresis; PR,
partialremission; ROM, range ofmotion.
cGVHD, the median number of EP procedures per patient
was 20.5, with a range of 6-48; the total number of lympho-
cytes (x 10'1treated per procedure was a median of 1.9 (range
of 0.4-4.2); and the total number of lymphocytes treated per
course was 20.5 (range of 2.0-144). The time between the
first and the last EP procedure was a median of 107.5 days
(range of 29-539) in the 18 patients with cGVHD.
A therapeutic 8-MOP level of >50 ng/mL for more
than half the EP treatments was achieved for 67% (n= 12) of
the cGVlID patients. The 8-MOP level was <50 ng/mL
(i.e., never in the therapeutic range) for all EP procedures in
28% (n= 5) of the cGVHD patients. Twelve patients had
unmeasurable 8-MOP levels at some time during their EP
therapy and two patients never achieved detectable levels of
8-MOP. Marked variability in 8-MOP levels were noted in
individual patients over time and from patient to patient in
this study (Table 3). There was no correlation between the
inability to absorb 8-MOP and gut pathology in the
cGVHD patients. For example, UPN 561, who never
achieved a detectable 8-MOP level, had bronchiolitis oblit-
erans and no known gut GVlID. In patients with acute
GVlID, the failure to absorb 8-MOP correlated with the
presence of gut GVlID.
The response rate with EP treatment was 3 of 6 for
patients with de novo cGVlID and 3 of 12 for patients with
cGVHD following acute GVlID. The pretreatment organ
system involvement by GVlID in the six EP responders and
the changes in the targeted GVlID parameters posttreat-
ment are shown in Table 4. The six responders included two
patients (UPN 565 and 444) with de novo skin cGVlID; one
patient (UPN 465) with de novo cGVlID of skin and mouth
plus hepatic dysfunction; one patient (UPN 525) with acu~e
progressing into chronic GVHD of the liver, who had preVI-
ously failed to respond to thalidomide, partially responde? to
3 months of PUVA, and had complete remission of bvef
cGVHD with EP; one patient (upN 650) with cGVHI? 0
the mouth and liver following acute GVlID; and one pane~t
(UPN 2105) who had improvement of acute grade IV skin
GVlID on EP and later was re-treated with EP for progres-
sive cGVHD of skin, mouth, and liver.The highest respon~
rate was 3 of 5 in the group of patients with skin cGVH
(includes patients with skin and with skin and mouth GVH~
plus hepatic dysfunction). Two patients (UPN 537 and 69
improved in the cGVlID parameter for which EP was start"
ed, but then developed progressive cGVlID in another
organ system after 22 and 30 EP procedures, respectively, at
which time EP was stopped for treatment failure. Th~ee
patients with bronchiolitis obliterans who were treated WIth
15, 18, and 22 EP procedures had no response or had docU"
mented progression on EP.
Toxicities
Overall toxicity was minor with the most common side
effect being complaint of GI upset. In one patient (U~N
465), GI upset was significant enough that EP was disconnn-
ued despite evidence of therapeutic benefit with the treatj
ment. Four patients with cGVlID (UPN 537, 650, 565, an
604) had catheter-related sepsis while on EP therapy. One
patient's (upN 444) right atrial catheter (RAC) broke and the
proximal part of the catheter had to be removed from the
right atrium under fluoroscopy. Although these incidentj
seemed unrelated to the EP procedures, the patient woul
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y epresent censored datapoints; , 95% confidence mterua.
:t have required a RAC in the absence of therapy with EP.
cether patient (UPN 2021) exp~rienced incr~ased red blood
p . and platelet transfusion requirements while on EP. One
batient (DPN 727) with acute grade IV liver GVHD who
I egkn E~ treatments on day 56 after BMT developed severebeu openla and lymphopenia by day 105, which may have
pee~ due to concurrent treatment with ganciclovir. A second
datJent (UPN 2105) who began EP on day 58 after BMT\V~eloped leukopenia after five EP treatments, recovered his
d Ite blood cell count when EP was stopped, and did not
evelop leUkopenia when rechallenged with EP on day 85.
th With a denominator of 509-procedures performed for
P
e.24 patients in this study (including 411 procedures in 18
atJent . h d dures in siWith s Wit cGVHD an 98 proce ures I SIX patients
c acute GVHD)-the above described 9 adverse events
onstitute a complication rate of 1.77%.
Sllr •
vlval and causes of death
of 1'he six patients with acute grade IV liver GVHD died
th progressive organ failure. Contributing causes of death in
o~e patients included cytomegalovirus pneumonia in two
;atients and Klebsiella sepsis with acute respiratory distress
Yndrome in one patient.
C 1'wo of the six patients with de novo cGVHD are alive.
n aUses of death in the others were relapsed acute myeloge-
OUs .leukemia and progressive bronchiolitis obliterans; pro-
~esslVe liver cGVHD with renal failure and fungal pneumo-
ultprogressive multi organ cGVHD and pneumonia; and
an ?WU, but presumed due to complications of cGVHD in
\Vcati~nt with a history of noncompliance and drug abuse,
o ~Ied at home after being lost to follow-up.evi1ve of the 12 patients with chronic following acute
ID are alive. The causes of death in the 7 others were
pro~ressive liver failure (two patients), spontaneous bacterial
Peritonitis complicating liver failure, progressive bronchioli-
BI1&MT
tis obliterans with cavitary lung lesions that were probably
fungal, hemolytic-uremic syndrome and hepatorenal failure
complicating severe progressive multiorgan system
cGVHD, progressive bronchiolitis obliterans and Aspergillus
pneumonia, and bilateral pneumonia.
The survival curve for cumulative probability of over-
all survival from the start of EP treatment in the 18
patients with cGVHD is shown in Figure 2. Five of the
survivors were EP responders; two survivors (UPN 726
and 732) had GVHD progression on EP and then
responded to salvage therapy with increased doses of PSE
plus thalidomide and CSA.
Predictors of response
We conducted a statistical analysis of EP treatment vari-
ables to see if predictors for a response to EP could be identi-
fied in the 18 patients with cGVHD. There was a statistically
significant difference between responders and nonresponders
for the following treatment variables: 8-MOP level of >50
ng/mL for at least one treatment (p = 0.04, Fisher's exact
test), maximum 8-MOP single dose (p = 0.02, Wilcoxon's
rank-sum test), and 8-MOP level of >75 ng/mL for two
doses (p = 0.04, Fisher's exact test). However, the other vari-
ables reflecting 8-MOP dose quantification (total dose across
all treatments, average dose, 8-MOP level of 50 ng/mL for
more than half the treatments, and 8-MOP level above 50
and 100 ng/mL for any two treatments) were not statistically
different between the responders and the nonresponders. \Ve
therefore concluded that the three 8-MOP treatment vari-
ables that had apparent statistical significance in our analysis
could not be interpreted as reflective of any meaningful cor-
relation between response and 8-MOP dose or levels in this
patient population. The difference between responders and
nonresponders approached statistical significance for the
number of procedures and the time between first and last
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procedures; however, these variables were likely to be surro-
gate markers for response because nonresponders stopped EP
at the time of documented progression and responders con-
tinued EP for a longer period of time. No correlation was
seen between pre- or posttreatment CD4/CD8 ratio and
response to EP.
DISCUSSION
UV irradiation can modify the functional behavior of
immunocompetent cells by causing cell membrane alter-
ations, modification of cell surface antigens, and interfer-
ence with cell-eell interactions, antigen presentation, and
cytokine release, as discussed in published reviews of this
topic by Deeg [38,39]. UV-irradiated lymphocytes fail to
function as stimulator cells in MLC [40]. T lymphocytes,
which are known to be involved in initiating and propagat-
ing GVHD after BMT, are extremely sensitive to UV irra-
diation. In animal models, the development of GVHD is
prevented by UV exposure of donor lymphocytes before
transplantation [41]. Exposure to UV light increases circu-
lating levels of inrerleukin-I (IL-l) but decreases macro-
phage expression of membrane-bound IL-l, increases pro-
duction oflL-4, and decreases production oflL-2 and inter-
feron 'Y [39]. UVA irradiation also induces alteration of cell
membrane antigenicity (i.e., immunogenicity). In murine
models, UVA-induced tumors are not rejected when trans-
planted into recipients, suggesting that UVA-induced modi-
fication of cell membrane antigenicity can prevent sensitiza-
tion and possibly induce a state of tolerance [42]. Numerous
reports in the photobiology literature have demonstrated
that UVB light (wavelength of 290-320 nm) and UVA light
(wavelength of 320-400 nm), in combination with photo-
sensitizers, can inhibit the expression of surface MIlC class
II antigens by the epidermal antigen presenting cells (i.e.,
Langerhans' cells) so that these cells lose their immunologic
function in the antigenic stimulation ofT lymphocytes [43].
Photochemotherapy, also known as PUVA therapy, is
the use of 8-MOP photoactivated by exposure of the skin to
UVA light. The photoactivated psoralen covalently binds to
the DNA helix between pyrimidine bases, cross-linking
DNA. The cross-linked DNA cannot replicate, so the pro-
liferative capacity of cells is suppressed [44]. PUVA therapy
suppresses the production of the pro-inflammatory
cytokines IL-l, IL-6, IL-8, and tumor necrosis factor
(TNF)-a by activated mononuclear cells [45]. PUVA thera-
py has been extensively used in the treatment of dermato-
logic diseases, including psoriasis, eczema, lichen planus,
atopic dermatitis, and vitiligo. Successful PUVA therapy for
cutaneous GVlID was first reported by Glazier et at. in
1984 and Hymes et at. in 1985 [46,47]. Subsequently, eight
published reports confirmed the efficacy and safety of
PUVA therapy in the treatment of cutaneous GVlID in
larger series of patients [18-25].
EP is the combination of photochemotherapy with
leukapheresis so that ex vivo exposure of peripheral blood
mononuclear cells to UVA light occurs. Edelson et at. intro-
duced the use of EP for the treatment of cutaneous T-cell
lymphoma in 1987 [37]. They demonstrated that extracor-
poreal exposure of a lymphocyte-enriched blood fraction of
1-2 J of UVA light per cm2 in the presence of a plasma 8-
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MOP concentration of 50 ng/mL efficiently compromise~
the viability of the irradiated lymphocytes. They also n?t~
the unpredictable absorption of 8-MOP after oral,a.dmlnJsdtration, attributed this to its low aqueous solubilIty, an
emphasized the importance of monitoring 8-MOP plasma
levels to guide dose adjustments [37]. Subsequently, EP ~as
used successfully for treatment of several autoimm~~e dlsd
eases, including rheumatoid arthritis, psoriatic arthnns, an
scleroderma [48-52]. EP was initially used in solid organ
transplantation as salvage therapy for drug-refractory acute
cellular rejection of cardiac allografts and subsequently ,h~s
been used successfullyto treat renal and lung allograft reJe d
tion [53-57]. Recently, important information has eme~ge f
regarding the potential use of EP for the prophylaXIS 0
acute rejection in heart transplant recipients [58,59]. ~ubsef
quent to the initial report of successfulEP treannent 10 2 0
3 patients with cGVHD in 1990 by Bolwell et al, [26], seve
eral investigators reported successful EP treatm~nt 0 f
refractory GVHD in isolated cases or small serIeS 0
patients, as outlined in Table 5 [60-66]. Snieci~ski hal
recently reviewed developments in clinical applicanons an
future prospects for EP therapy [67]. 4
This summary of our results of the EP treannent of 2
patients with refractory acute and chronic GVHD repre-
sents the largest single institution experience with EP thera-
py of GVlID. Although this study of EP irivolved a grOUP
of refractory patients with advanced GVlID, it demon~trat;
ed some efficacy for EP in the treatment of drug-reslst~
cGVHD. The high response rate in patients with S f
cGVlID was not unexpected because previous reportS 0
PUVA therapy had documented the efficacy of pho-
tochemotherapy in the treatment of cutaneous cGVIIDdOne of the EP responders (UPN 565), however, h,a
received 2 months of PUVA therapy before treatment WI~
EP and, while undergoing PUVA therapy, had documente
progression of GVlID with increased skin blistering, ulcer-
ation, and thickening. His improvement with EP SUgge,% a
role for EP in patients with cutaneous cGVlID who er er
fail to respond to or cannot tolerate PUVA therapy. 'The
complete resolution of liver cGVlID with EP in a patient
(UPN 525) who had previously received PUVA therapY
with only stable to slightly improved liver cGVlID also sUf
gests that EP may be used as salvagetherapy in patients.W rs
do not respond to PUVA therapy. There were three panent
with hepatic dysfunction due to cGVlID in our study pop~­
lation (UPN 465, 525, and 650) who had improvement ~n
their liver function test abnormalities with EP, as shown In
Table 4. Their response to EP suggests that it may h~ve, a
role in the therapy of patients with cGVlID who have 11111lt-
ed hepatic involvement. Our experience also confirms th~t
the highest response rate for EP occurs in patients with skid
cGVlID, as reported in other trials listed in Table 5. Base
on our experience, EP does not have a role in the treatment
of patients with bronchiolitis obliterans.
Because the clinicopathology of cGVlID resembles an
amalgam of autoimmune diseases, it is not surprising that
EP therapy, which has documented efficacyin the treanne?t
of various connective tissue disorders, is also efficaciouS In
the treatment of cGVlID. The failure of EP to alter the
course of grade IV drug-refractory acute liver GVlID in
our study suggests that the amplification of pro-inflammato-
ExtracorporeaJ Photochemotherapy and GVHD
T;i)'e 5 EP'
• In treatment ofGVHD: other trials
CSA + PSE 2/] (66%)
CSA + PSE 4/4 (100%)
NA ]/] (100%)
CSA + PSE ]/S (60%)
CSA + PSE III (100%)
CSA, PSE, Imuran 5/5 (100%) skin
OIS (0%) other
organs
CSA + PSE III (100%)
CSA III (100%)
Adjunct
Immunosuppression Response rateTreatment protocol
2 proc q. 4 weeks for 6 months
2 proe q. 2 weeks for 3 months
2 proe q. ] weeks
2 proe q. 4 weeks for 3 months
2 proe q. 4 weeks
2 proe q. 2 weeks or
9-14 months
2 proe q, 2 weeks or 3 months
and q. 4 weeks for] months
2 proe q. 2 weeks for] months
then tapering for 9 months
Entry criteria
Refractory chronic skin GVHD
Refractory chronic skin and liver GVHD
Refractory chronic skin, mouth,
gastrointestinal, and ocular GVHD
Refractory chronic skin, mouth,
liver, and lung GVHD
Refractory chronic skin GVHD
Refractory chronic skin GVHD
Refractory chronic skin GVHD
Chronic skin and liver GVHD
Investigator---.~----------_-...:..-_-----------------------------
:olwell et a/. (1990) [26]
100111 et al. (1991) [60]
~wSlanOWSkl et at. (1994) [61]
oSsettl et al. (1995) [62]
Schoon
elllan et a/. (1995) [6]]
Volc.Plaher et a/. (1996) [64]
CrOvettl et al. (1996) [65]
Dall'A I
III co et a/. (1997) [66]
-N<1, not av '1 hiau« e; Proc, procedures.
1)' eytokines and tissue injury which occurs in late stages of
aCUt G 'i e VHD, is too advanced to be affected by thetrn~Unomodulatoryeffects of photochemotherapy. Pho-
Oe emotherapy may have a role in the early therapy of
aCUte GYRD, in combination with standard steroid treat-~ent, but this has yet to be clinically tested. Because several~ves?gators have demonstrated the efficacy of UV irradia-
of In preventing transplant-induced alloreactivity in ani-rn~ models (as discussed above), further exploration of the~~ of photochemotherapy in the prophylaxis of acute
ID after human BMT may also be warranted.
MoWe were unable to correlate response to EP with 8-
P levels, number of lymphocytes treated, or patterns of
~re-. and posttreatment CD4/CD8 ratio. Perhaps more
htalled immunological studies of lymphocyte and macro-
P age function and cytokine production would have allowed
Us to identify patient characteristics that correlated with
responseto EP.
dr We c?nclude that EP ~ay be.useful in the tre?~ent of
hug-resistant cGVlID with minor overall toxicity, We
byPothesize that the response rate to EP may be improvedl the use of Uvadex, an injectable psoralen that is added to
h.photoactivation bag ex vivo, which allows for consistent
ahlev~ment of therapeutic 8-MOP levels in the buffy coat~ M'esls product, thereby eliminating the wide variability of
1\- OP levels that is seen with an oral psoralen formulation.
Study ofEP with Uvadex is already in progress at Call to~est this hypothesis. We also suspect that the response rateG'~~ may be better if it is used earlier in the course of
v nD. An evaluation of the efficacy of EP therapy in~GVIID by a prospective randomized study conducted early
~n the Course of the disease, either in combination with stan-
f ~rd CSA and PSE therapy or as first salvage therapy afterhtlure to respond to CSA and PSE, is needed to determine
t e place of EP in the armamentarium of therapies for~GVlID. It would be interesting if future clinical studies
Included detailed assays of immunologic function pre- and
P?st-therapy in an effort to elucidate the biologic mecha-
tUsms by which EP exerts its immunomodulatory effect and
to correlate patient characteristics with response.
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